Finvest
ALNY Biotechnology · RNAi · Commercial biotech · Rare disease · Thesis updated June 12, 2026

AMVUTTRA powers Alnylam, with strings attached

01 Running thesis

A launch that changed the company

Alnylam has moved from promising biotech to a real commercial drug company. The key reason is AMVUTTRA. In Q1 2026, the TTR franchise, AMVUTTRA plus ONPATTRO, produced $910 million in global revenue, up 153% from Q1 2025. That launch is now the center of the story.

The bull case is simple. Alnylam leads RNAi, has several approved drugs, and has large partners like Novartis, Roche, Sanofi, and Regeneron. Its Alnylam 2030 plan targets 25% plus total revenue compound annual growth and about a 30% non-GAAP operating margin by 2030. Non-GAAP means the company excludes some accounting costs to show what it thinks the core business earns.

The bear case is also real. AMVUTTRA faces oral ATTR cardiomyopathy drugs from Pfizer and BridgeBio. The company is very tied to one franchise. If AMVUTTRA slows, the whole profit story weakens.

The stock also has a price and trust question. Royalty payments on AMVUTTRA and heavy Phase 3 research spending mean profits may not scale as fast as some investors hoped. Two FDA untitled letters about AMVUTTRA promotion in seven months also make the commercial story less clean.

Apr 2026→Q1 2026 confirmed the strength of AMVUTTRA in cardiomyopathy, with $1.036 billion of net product revenue and $910 million from the TTR franchise. The update was mixed because management also framed 2026 non-GAAP operating margin near 30% and the filing added a new FDA untitled letter risk.
Feb 2026▲Alnylam set 2026 net product revenue guidance at $4.9 billion to $5.3 billion, with the TTR franchise expected to drive most of the growth. The Alnylam 2030 plan gave investors clearer long-term targets.
Feb 2026▲The 2025 Form 10-K showed Alnylam reached its first full-year GAAP profitability. Product revenue grew to about $3.0 billion, mainly from the TTR franchise.
Oct 2025▼The Q3 2025 filing disclosed a subpoena from the U.S. Attorney's Office related to government price reporting. That added a legal overhang to an otherwise strong AMVUTTRA launch.
Jul 2025▲Q2 2025 gave the first strong numbers for the AMVUTTRA cardiomyopathy launch. AMVUTTRA revenue reached $492.0 million, and the company raised full-year 2025 product revenue guidance.
May 2025▲Early launch checks were positive after AMVUTTRA's ATTR cardiomyopathy approval. Management said the drug was added to more than half of about 170 key health systems within four weeks.
02 Business model

Drug sales first, partner checks second

Alnylam makes money in three ways: selling its own drugs, collecting collaboration revenue from partners, and earning royalties on partner-sold drugs. Its four self-marketed products are AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.

The direct drug business is now much larger than the rest. In Q1 2026, net product revenue was $1.036 billion. The TTR franchise made $910.4 million of that, showing how concentrated the business has become around AMVUTTRA and ONPATTRO.

Partner revenue adds useful funding and validation. Novartis sells Leqvio, Sanofi sells Qfitlia, Roche is partnered on zilebesiran, and Regeneron is involved in complement disease work. Royalty revenue was $49.0 million in Q1 2026, up 85% from Q1 2025, mainly from higher Leqvio sales.

The model breaks if AMVUTTRA loses share, pricing gets worse, or regulators force changes in promotion. International TTR revenue still grew 35% from Q1 2025, but it had a small sequential decline after a mandatory Germany price adjustment tied to the ATTR cardiomyopathy launch.

03 Product portfolio

Approved drugs and big bets

Growth engine

AMVUTTRA

AMVUTTRA treats hATTR amyloidosis with polyneuropathy and ATTR cardiomyopathy. It is the main reason product revenue jumped in Q1 2026.

Steady

ONPATTRO

ONPATTRO treats the polyneuropathy form of hATTR amyloidosis. It is older than AMVUTTRA, and some patients have switched to AMVUTTRA.

Steady

GIVLAARI and OXLUMO

GIVLAARI treats acute hepatic porphyria, and OXLUMO treats primary hyperoxaluria type 1. They give Alnylam rare disease revenue outside TTR.

Cash cow

Leqvio and Qfitlia royalties

Leqvio is sold by Novartis, and Qfitlia is sold by Sanofi. These drugs can add high-margin royalty revenue without Alnylam running the full sales effort.

Option

Nucresiran

Nucresiran is a next-generation TTR program. A Phase 3 cardiomyopathy study began in H1 2025, and success could help defend the TTR franchise into the 2030s.

Option

Zilebesiran

Zilebesiran is an RNAi treatment for hypertension, partnered with Roche. It could move Alnylam into a much larger heart disease market if late-stage trials work.

Option

ALN-HTT02 and obesity program

ALN-HTT02 is in Phase 1 for Huntington's disease, with initial data expected in H2 2026. Alnylam also began a Phase 1 adipose-targeted obesity and weight management program in Q1 2026.

04 Business segments

Q1 mix is mostly product sales

Net Product Revenues89%growing fast
Net Revenues from Collaborations7%declining
Royalty Revenue4%growing fast

This mix uses Q1 2026 revenue categories: net product revenue, collaboration revenue, and royalty revenue. Product sales dominate, and most of that product revenue comes from the TTR franchise.

05 Risk factors

What could break the story

AMVUTTRA growth slows

High impact · Medium odds

Alnylam depends heavily on AMVUTTRA and the broader TTR franchise. The franchise made $910.4 million in Q1 2026, so a slowdown would hit growth and profit at the same time. Competition from Pfizer and BridgeBio gives doctors and patients other choices.

We watchQuarterly TTR franchise revenue, U.S. new patient starts, and any share gains by Pfizer or BridgeBio ATTR cardiomyopathy drugs.

Margins disappoint

Medium impact · Medium odds

Management has pointed investors to about a 30% non-GAAP operating margin for 2026. That is held down by AMVUTTRA royalty payments and heavy Phase 3 research spending. If investors expected much higher margins, the stock could struggle even while revenue grows.

We watchNon-GAAP operating margin guidance, R&D spending growth, and management comments on AMVUTTRA royalty burden.

FDA promotion scrutiny gets worse

Medium impact · Medium odds

In April 2026, the FDA sent Alnylam an untitled letter saying parts of the AMVUTTRA consumer website were false and misleading. That followed a September 2025 untitled letter about a direct-to-consumer TV ad, which later received a close-out letter. More action could force changes in marketing and slow outreach to patients.

We watchFDA response letters, close-out status for the April 2026 website letter, and any change in AMVUTTRA advertising.

Government price reporting investigation

High impact · Low odds

Alnylam received a subpoena from the U.S. Attorney's Office for the District of Massachusetts related to government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI. The company has produced records, but the filing did not give details on possible claims or dollar exposure. If violations are found, penalties and management distraction could matter.

We watchNew 10-Q or 10-K disclosures, settlement news, or details on the specific price reporting issues under review.

Pipeline bets fail

Medium impact · Medium odds

Alnylam needs follow-on programs to make the 2030 plan more than an AMVUTTRA story. Nucresiran, zilebesiran, mivelsiran, ALN-HTT02, and the obesity program all carry clinical risk. Failed trials would not erase the current business, but they would lower the long-term growth case.

We watchALN-HTT02 Phase 1 data in H2 2026, nucresiran Phase 3 progress, and Roche updates on zilebesiran.
06 Quick answers

In one breath

What does Alnylam actually do?

Alnylam develops RNAi medicines. RNAi drugs are designed to silence, or turn down, genes that help cause disease.

Why is AMVUTTRA so important to Alnylam?

AMVUTTRA is now the main growth engine after its ATTR cardiomyopathy launch. In Q1 2026, the TTR franchise that includes AMVUTTRA produced $910.4 million in revenue.

Is Alnylam profitable?

Alnylam reported its first full-year GAAP profitability in 2025. Management is pointing to about a 30% non-GAAP operating margin for 2026, but royalties and research spending limit how fast profits scale.

What is the biggest risk for ALNY stock?

The biggest business risk is that AMVUTTRA growth slows in ATTR cardiomyopathy. Other key risks are FDA scrutiny of promotion, a government price reporting subpoena, and trial failures in the pipeline.